Results 151 to 160 of about 48,388 (273)

Stage I Seminoma of the Testis [PDF]

open access: yes, 1991
Allhoff, E. P.   +4 more
core   +1 more source

Cancer heterogeneity explored through immune cell deconvolution of the tumor microenvironment

open access: yesQuantitative Biology, Volume 14, Issue 3, September 2026.
Abstract Cancer is a highly heterogeneous disease, characterized by significant variability across multiple dimensions. This diversity has been extensively studied from various perspectives. In this study, we aim to examine cancer heterogeneity through the lens of immune cell composition within the tumor microenvironment.
Limin Jiang   +4 more
wiley   +1 more source

Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High‐Dose Chemotherapy With Autologous Hematopoietic Stem‐Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors

open access: yesPediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Although most malignant germ cell tumors (GCTs) are highly curable with cisplatin‐based therapy, options for patients with multiply relapsed/refractory disease remain limited. For this population, we report the first pediatric use of gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) as part of sequential cycles of high‐dose ...
Maria Frost   +10 more
wiley   +1 more source

Aosta Valley animal cancer registry: A collaborative initiative for monitoring cancer burden in animals

open access: yesVeterinary Record Open, Volume 13, Issue 1, June 2026.
Abstract Background Animal cancer registry data are important for monitoring animal health, for prevention and research in veterinary medicine, and for comparative oncology. Since people and animals share the same environment and are exposed to many common risk factors, cancer patterns in animals may have a sentinel function for human health.
Claudio Trentin   +10 more
wiley   +1 more source

Extracranial, Extragonadal Germ Cell Tumors: A Multicenter Australian Case Series

open access: yesAsia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 404-410, June 2026.
Extragonadal germ cell tumors (EGCTs) are rare, with limited prospective data to guide treatment or inform prognosis. Incidence and treatment patterns of EGCT in Australia reflect international data and practices. Compared to testicular primaries, the prognosis of EGCT is poor, especially for primary mediastinal non‐seminoma.
Kar Ven Cavan Chow   +19 more
wiley   +1 more source

Cancer Incidence in People With Intellectual Disability and Down Syndrome in Australia: A Cohort Study

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Objective There is inconsistent data on cancer risk in people with intellectual disability. Our primary objective was to compare the incidence of cancer in people with and without intellectual disability. Methods and Analysis A cohort study using linked population‐based administrative and cancer registry data in New South Wales, Australia 2001–
Julian Trofimovs   +4 more
wiley   +1 more source

Dietary Ergothioneine as a Novel Anti‐Aging Nutraceutical: Mechanisms, Bioavailability, and Future Perspectives

open access: yesFood Frontiers, Volume 7, Issue 3, May 2026.
ABSTRACT Ergothioneine (EGT), a natural thiol derivative, has gained attention as a geroprotective nutraceutical. Preclinical research shows EGT scavenges free radicals, maintains mitochondrial integrity, slows telomere erosion, and regulates proteostasis via autophagy and senescent cell clearance.
Tian‐Tian Tian   +3 more
wiley   +1 more source

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B‐Cell Lymphoma (CLSG‐CNS‐01): A Randomized, Multicenter, Prospective Phase 3 Trial

open access: yesHematological Oncology, Volume 44, Issue 3, May 2026.
ABSTRACT The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B‐cell lymphoma (DLBCL). Treatment consisted of six cycles of R‐CHOP + 2xR or DA‐EPOCH‐R + 2xR. Patients with intermediate or high‐risk
H. Mocikova   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy